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Certain high-risk (HR) human papillomavirus (HPV) types are a necessary cause for the development of
cervical disorders. Women with persistent HR HPV infections have an increased risk of developing high-grade
cervical lesions, compared with those who have no or low-risk HPV infections. Therefore, implementation of
HPV detection into cervical screening programs might identify women at risk of cervical cancer. Several HPV
detection methods with different sensitivities and specificities are available. Recently, a new PCR-based tech-
nique, the Roche AMPLICOR HPV Test, was developed. This test recognizes a group of 13 HR HPV types si-
multaneously. This study was undertaken to validate and compare HPV detection in 573 cervical scrape spec-
imens by the AMPLICOR HPV Test and the INNO-LiPA HPV detection/genotyping assay (SPF10-LiPA system
version 1). Human -globin was not detected in nine specimens, which were therefore excluded from the
comparison. Eleven scrape specimens containing HPV type 53 or 66 were also excluded from the comparison
because these (probably) HR HPV types cannot be detected by the AMPLICOR HPV Test. The results of HPV
detection by the Roche AMPLICOR HPV Test were confirmed by INNO-LiPA HPV detection/genotyping assay
in 539/553 cases, showing an absolute agreement of 97.5% with a Cohen’s kappa of 0.9327, indicating almost
complete similarity of the two tests. Like the INNO-LiPA HPV detection/genotyping assay, the AMPLICOR
HPV Test was sensitive, specific, feasible, and easy to handle. The value of the Roche AMPLICOR HPV Test
with a broad-spectrum HR HPV detection has to be determined in prospective clinical studies.
Cancer of the uterine cervix is a major cause of death. Al-
though screening programs to identify precursor lesions of
cervical cancer have contributed to a reduction in mortality
and morbidity due to this disease, 500,000 new cases of invasive
cervical cancer are diagnosed annually and 230,000 women die
because of this disease (29). In developing countries, cancer of
the cervix is the most frequent female malignancy and is re-
sponsible for about 24% of all cancers in women. In developed
countries, cervical cancer accounts for 7% of all female cancers
(29).
The human papillomavirus (HPV) family consists of many
different types; more than 100 types have been identified to
date, of which 40 types have been detected in the anogenital
mucosa (6, 11, 47). Several HPV types, such as types 16, 18, 31,
33, and 35, have been implicated as sexually transmitted agents
with an etiological role in cervical carcinogenesis (27), whereas
other types, such as types 6 and 11, are frequently detected in
benign lesions such as condylomata acuminata. Therefore,
HPV types 6 and 11 are termed low-risk (LR) HPV types, and
HPV types involved in carcinogenesis (such as types 16 and 18)
are termed high-risk (HR) HPV types (27).
Infection by HR HPV types has been demonstrated in al-
most 100% of cervical carcinomas (42). Studies of the onco-
genic potential of these HPV types have clearly demonstrated
that HR HPVs are a necessary cause for the development of
cervical cancer (4, 7, 17, 19, 34).
It is generally accepted that women infected with an HR
HPV type are thus at higher risk of developing cervical cancer
than those who are not infected with HPV or who are infected
with one of the LR HPV types (10, 20, 30). Incorporation of
HPV tests into screening programs might identify women who
are at risk of developing invasive cervical cancer. Indeed, sev-
eral studies have demonstrated the potential relevance of HPV
testing in cervical cancer screening programs and the manage-
ment of patients with slight abnormal cytology (2, 5, 8, 10, 34,
37, 42). Furthermore, the absence of HR HPV in cervical
smears would permit less aggressive management of women
with mild or equivocal cytological abnormalities because they
are unlikely to progress (16, 26, 33). The importance of HPV
in the genesis of cervical neoplasm suggest that diagnosis of a
specific HPV infection would dictate a particular clinical out-
come and hence be useful in patient management. Because of
the large number of both HR and LR anogenital HPV types,
which are all able to induce cervical disorders, the detection
* Corresponding author. Mailing address: Department of Medi-
cal Microbiology, Radboud University Medical Center Nijmegen,
NCMLS/NUCI, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
Phone: 0031 24 3614356. Fax: 0031 24 3540216. E-mail: w.melchers
@ncmls.ru.nl.
2662
and typing of a broad spectrum of different HPV types are
mandatory, certainly in the phase in which the definitive pro-
gression markers have yet to be established.
Since HPV cannot be cultured efficiently and the clinical
performance of serological assays is poor, diagnosis of HPV
infection is almost entirely based on molecular tools (14). Be-
fore the era of amplification technology, Southern blot, dot
blot, filter in situ, and in situ hybridization assays using HPV
type-specific probes were generally used to detect and geno-
type HPV (23, 24, 43). However, applicability was limited be-
cause of low sensitivity, low specificity, or both or because of
complex execution of techniques and low potential for auto-
mated implementation, which is required for processing a large
number of clinical samples in a population-based screening
design. New amplification techniques, such as PCR, nucleic
acid sequence-based amplification, and ligase chain reaction,
and advances in old techniques, including liquid hybridization
(e.g., hybrid capture) (8), have revolutionized the potential of
molecular screening for HPV in the past decade.
General detection assays, with a broad spectrum of specific-
ity for HPV, are now widely used for the detection of HPV in
clinical cervical material (2, 12, 22, 31), although the Hybrid
Capture II assay (Digene) is the only commercially available
HPV screening test on the market. The Hybrid Capture II
assay for HPV DNA detection is a liquid-based hybridization
assay capable of detecting 13 HR HPV genotypes simulta-
neously (1). In 2003, a newly developed PCR-based technique,
the Roche AMPLICOR HPV Test, was launched. This test is
also capable of detecting 13 HR HPV types, with simultaneous
assessment of the presence of the human -globin gene as a
positive control. This test could, in principle, be used for
screening purposes. However, no data are currently available
on the performance and value of the assay in a clinical setting.
The purpose of this study was to examine the utility of the
AMPLICOR HPV Test by comparing results with those ob-
tained using the INNO-LiPA HPV detection/genotyping assay.
The INNO-LiPA HPV detection/genotyping assay is capable
of detecting and genotyping 25 different HPV types simulta-
neously and has proved to be sensitive, specific, simple, and
rapid in the assessment of HPV (14, 21). A total of 573 anon-
ymous cervical samples were tested by both assays, and the
results were compared.
MATERIALS AND METHODS
Cervical scrape specimens were obtained from 573 women seeing a gynecol-
ogist for routine cervical screening. Specimens were collected using the Cervex-
brush (Roovers, Oss, The Netherlands) and processed using a liquid-based
(Cytyc) approach that provides monolayer distributions for cytological assess-
ment and the possibility of isolating DNA for HPV detection assays. This method
has received approval for clinical use from the U.S. Food and Drug Adminis-
tration (18, 36). Cytological classification was performed by an experienced
cytopathologist.
Specimen preparation. For isolation of nucleic acid from cervical scrape spec-
imens in liquid cytology medium, the MagnaPure LC Isolation station (Roche
Applied Science) was used; 200 l of material was isolated using the Total
Nucleic Acid isolation kit (Roche Applied Science) as described by the manu-
facturer. Nucleic acid was resuspended in a final volume of 100 l; 10 l was used
for PCR analysis.
After isolation of DNA, samples were tested for the presence of HPV by the
INNO-LiPA HPV detection/genotyping assay and the Roche AMPLICOR HPV
Test. All HPV tests were performed by investigators unaware of the cytological
status or the results of the comparative HPV detection test.
INNO-LiPA HPV detection and genotyping. (i) PCR amplification of HPV
DNA. Broad-spectrum HPV DNA amplification was performed using a short
PCR fragment assay (INNO-LiPA HPV detection/genotyping assay, SPF10 sys-
tem version 1, manufactured by Labo Biomedical Products bv, Rijswijk, The
Netherlands). This assay amplifies a 65-bp fragment of the L1 open reading
frame and allows detection of at least 43 different HPV types (15, 21). The SPF10
PCR was performed with a final reaction volume of 50 l containing 10 l of the
isolated DNA sample, 10 mmol/liter Tris-HCl (pH 9.0), 50 mmol/liter KCl, 2.0
mmol/liter MgCl2, 0.1% Triton X-100, 0.01% gelatin, 200 mol/liter of each
deoxynucleoside triphosphate, 15 pmol each of the forward and reverse primers
tagged with biotin at the 5end, and 1.5 U of AmpliTaq Gold (Perkin-Elmer).
The mixture was incubated for 9 min at 94°C, 40 cycles of 45 s at 45°C, and 40
cycles of 45 s at 72°C, with a final extension of 5 min at 72°C. Each experiment
was performed with separate positive and negative PCR controls.
The presence of HPV DNA was determined by hybridization of SPF10 am-
plimers to a mixture of general HPV probes recognizing a broad range of HPV
genotypes, in a microtiter plate format, as described previously (15).
(ii) HPV genotyping by reverse hybridization using the INNO-LiPA HPV
genotyping system. A poly(dT) tail was enzymatically added to the 3 end of each
of 25 oligonucleotides specific for 25 different types, namely, types 6, 11, 16, 18,
31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68/73, 70, and
74. The tailed probes were applied as horizontal lines to membrane strips (man-
ufactured by Labo Biomedical Products bv, Rijswijk, The Netherlands). The
HPV genotyping assay was performed as described previously (14). Briefly, equal
volumes (10 l each) of the biotinylated PCR products and denaturation solution
(400 mmol/liter NaOH, 10 mmol/liter EDTA) were mixed in test troughs and
incubated at room temperature for 5 min, after which 1 ml of prewarmed (37°C)
hybridization solution (3 SSC [1 SSC is 0.15 mol/liter NaCl plus 0.015 mol/
liter sodium citrate], 0.1% sodium dodecyl sulfate) was added, followed by the
addition of one strip per trough. Hybridization was performed for 1 h at 50 
0.5°C in a closed water bath with back-and-forth shaking. The strips were then
washed twice with 1 ml of wash solution (3 SSC, 0.1% sodium dodecyl sulfate)
at room temperature for 20 s and once at 50°C for 30 min. Following this
stringent washing, strips were rinsed twice with 1 ml of a standard rinse solution
(14). Strips were then incubated on a rotating platform with an alkaline phos-
phatase-labeled streptavidin conjugate diluted in a standard conjugate solution,
at 20 to 25°C for 30 min, after which strips were washed twice with 1 ml of rinse
solution and once with standard substrate buffer; color development was initiated
by the addition of 5-bromo-4-chloro-3-indolylphosphate and nitroblue tetrazo-
lium to 1 ml of substrate buffer. After 30 min of incubation at room temperature,
the color reaction was stopped by aspiration of the substrate buffer and addition
of distilled water. After drying, the strips were visually interpreted using a grid.
AMPLICOR HPV Test. The AMPLICOR HPV Test utilizes amplification of
target DNA by PCR followed by nucleic acid hybridization for the detection of
13 HR HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68).
PCR amplification of HPV DNA. The AMPLICOR HPV Test amplifies a
sequence of nucleotides within the polymorphic L1 region of the HPV genome
that is approximately 165 bp in length. A pool of 12 HPV primers present in the
master mix (components comprise nucleotides, enzyme cofactor, Taq DNA poly-
merase, AmpErase enzyme [Applied Biosystems], buffers, and primers) is de-
signed to amplify DNA from 13 HR HPV types. Capture probe sequences are
located in polymorphic regions of L1 bound by these primers. An additional
primer pair targets the human -globin gene (268-bp amplicon) to provide a
control for cell adequacy.
PCR was performed with a final reaction volume of 100 l containing 50 l
AMPLICOR HPV master mix and 10 l of the isolated DNA. The mixture was
incubated for 2 min at 50°C and 9 min at 95°C, followed by 40 cycles of 30 s at
95°C, 45 s at 54°C, and 30 s at 72°C, with a final extension at 72°C for at least 10
min to a maximum of 1 h.
Hybridization. After amplification, 100 l of AMPLICOR denaturation solu-
tion was added to each PCR tube, followed by incubation for 10 min at room
temperature to allow complete denaturation. Two separate 96-microwell plates
were used for detection of amplified HPV and -globin. AMPLICOR hybrid-
ization buffer (100 l) was added to each well of both plates; 25 l of denatured
amplified sample was then added to the appropriate wells of each detection
plate. The plates were covered and incubated for 1 h at 37°C to allow the
amplicons to bind to the oligonucleotide probes.
Detection. The plates were washed five times with AMPLICOR wash buffer
using a BioTek MWP washer to remove unhybridized material. AMPLICOR
avidin-horseradish peroxidase conjugate (100 l) was pipetted into the wells, and
the plates were covered and incubated for 15 min at 37°C. The plates were again
washed as described above. A 100-l aliquot of AMPLICOR substrate, contain-
ing tetramethylbenzidine and hydrogen peroxide, was added to each well, and
plates were incubated in the dark at room temperature for 10 min to allow color
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development. AMPLICOR stop reagent (100 l) was pipetted into the wells, and
the optical density of the reaction mixture was measured at 450 nm in a BioTek
MWP autoreader. An absorbance reading of greater than 0.2 was considered
positive for the presence of HPV and -globin.
Agreement was measured by absolute agreement, as well as Cohen’s kappa
statistics, a measure of the agreement between two methods that is in excess of
that due to chance.
RESULTS
A total of 573 cervical samples were available for compari-
son. In 9/573 samples (1.5%), the human -globin gene did not
test positive by the AMPLICOR HPV Test, and these samples
were therefore excluded from the comparison.
After HPV detection by both tests, INNO LiPA genotyping
was performed in order to compare the two test results. HPV
genotyping was performed on the positive samples. As the
INNO LiPA HPV detection/genotyping assay detects HR
HPV types, LR HPV types, and HPV X individually, in
contrast to the AMPLICOR HPV Test, which detects only
13 HR HPV types as a group, the samples testing positive
for LR HPV DNA or HPV X by the INNO LiPA HPV
genotyping assay were considered negative in the compari-
son (55 samples). Of these 55 samples, 21 samples contained
LR HPV DNA and 34 samples contained HPV X. In 51 of
these 55 samples, the cytological result was normal whereas
two samples were cytologically diagnosed as very mild dys-
plasia (later termed as atypical squamous cells of undeter-
mined significance [ASCUS]), one scrape specimen was di-
agnosed as mild dysplasia, and for one scrape specimen no
diagnosis could be assessed. In four patients HPV6 was
detected, in one patient HPV42 was detected, in five pa-
tients HPV44 was detected, in three patients HPV54 was
detected, in 1 patient HPV70 was detected, in three patients
HPV74 was detected, and in four patients double infections
with LR HPV types were detected.
Although HPV53 and HPV66 are considered probably car-
cinogenic (27), these genotypes are not included in the AM-
PLICOR HPV Test and were therefore excluded from the
direct comparison although HPV53 was found by INNO-LiPA
HPV genotyping in seven patients with a normal cytological
result and HPV66 was found in three patients with a normal
cytological result and in one patient with a normal smear result
both types 53 and 66 were detected. So the final comparison
was made for 553 cervical samples.
HR HPV DNA was detected by both the AMPLICOR HPV
Test and the INNO LiPA HPV genotyping assay in 132/553
cervical samples (24%). A total of 407/553 cervical samples
tested negative for HPV DNA in both tests (74%). Therefore,
both tests showed corroborative results for HR HPV types in
539/553 samples (Table 1 and Table 2), demonstrating a con-
cordance of 97.5% and   0.9327 (confidence interval, 0.8980
to 0.9675).
The relationship between concordant HPV detection for
both tests and cytological classification is shown in Table 2. HR
HPV DNA was detected by both methods in 88/469 scrape
specimens (19%) from women diagnosed with a normal cyto-
logical classification. HPV positivity increased with the severity
of the cytological diagnosis: HR HPV DNA was detected in
63% (19/30) of women with ASCUS, 67% (18/27) of women
with mild to moderate disorders, and 83% (5/6) of women with
severe dysplasia. HPV DNA was detected in 29% (2/7) of
women in whom cytological results could not be ascertained
due to sampling errors. A single HR HPV infection was de-
tected by the INNO-LiPA HPV detection/genotyping assay in
87/132 HPV-positive scrape specimens (66%). HPV types 16,
18, 31, 33, 51, and 52 accounted for 77% of the single HPV
infections, with HPV type 16 being the most common (ac-
counting for 34% of all single infections). In total, 45/132
positive cervical scrape specimens (34%) contained two or
more HPV types (Table 1). Multiple (i.e., two or more) infec-
tions as a proportion of total infections were seen in all cyto-
logical classifications (normal, 38%; ASCUS, 17%; mild/mod-
erate dysplasia, 19%; severe dysplasia, 17%; no diagnosis,
14%). The distribution of the individual HPV types within the
multiple infections showed no statistically significant difference
between the different cytological classifications, probably due
to the unequal numbers in the groups. Since the AMPLICOR
HPV Test only determines positivity, multiple infections could
not be assessed by this method.
In 14 cases (2.5%), the HPV test results were discordant, as
shown in Table 3. The AMPLICOR HPV Test detected HR
HPV DNA in five cervical scrape specimens in which the
INNO LiPA HPV genotyping assay was either negative (one
case), positive for LR HPV (one case), or positive but where
the type could not be determined (HPV X). In nine cases, the
AMPLICOR test results were negative, whereas the SPF10-
LiPA detected HR HPV types in these nine cases. HPV18 and
-31 were both missed in one case, HPV33 was missed twice,
and HPV51 and HPV52 were missed in three cases by the
AMPLICOR test. Twelve cervical scrape specimens in the
discordant group were cytologically diagnosed as normal, one
smear was classified as ASCUS, and the other as mild/moder-
ate dysplasia.
DISCUSSION
Infections with HR HPV are now considered, beyond rea-
sonable doubt, to be a necessary cause of the development of
cervical cancer (3, 45). Women with persistent cervical HR
HPV infections have a 100- to 300-fold increased risk of de-
veloping a high-grade cervical intraepithelial lesion (CIN 3)
(13, 28, 30, 32, 42, 44). Although the sensitivity of HR HPV
detection for identifying women with high-grade cervical intra-
epithelial neoplasia (CIN) or cervical cancer appears to be
higher than that of conventional cytology, especially in women
with borderline and mild dysplastic smear results, its clinical
specificity is lower (1, 9, 33). Large randomized controlled
trials are currently being conducted to investigate whether the
addition of HR HPV detection to conventional cytology may
TABLE 1. Overview of the 553 samples tested by the AMPLICOR
HPV Test and SPF10-LiPA for HR HPV genotypes only
a
Test result
No. of samples
TotalSPF10-LiPA
positive
SPF10-LiPA
negative
AMPLICOR HPV positive 132 5 137
AMPLICOR HPV negative 9 407 416
Total 141 412 553
a Absolute agreement, 97.5%; kappa  0.9327 (confidence interval, 0.8980 to
0.9675).
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improve the effectiveness of organized cervical cancer screen-
ing programs (5, 40). Identification of HR HPV types may
identify women with an increased risk of cervical disease and
may therefore provide additional clinical value (10). Indeed, in
the United States, the American College of Obstetrics and
Gynecology and the American Cancer Society both approved
that women over 30 years old should be screened with an HPV
DNA test combined with a cytological examination.
If HPV testing is to be introduced into cervical cancer pre-
vention programs, then standardized, reliable, and accurate
HPV tests are warranted (35). The newly developed, PCR-
based AMPLICOR HPV Test may fulfill these demands. How-
ever, the test should be evaluated in a clinical laboratory set-
ting. In this study, we compared HPV status in cervical scrape
specimens using the AMPLICOR HPV Test and the INNO
LiPA HPV detection/genotyping assay. Both systems appeared
to be highly concordant, with a kappa of 0.9235, demonstrating
highly similar outcomes.
In nine cases, no human -globin was detected, suggesting
an inadequacy of cellular material, probably due to sampling
errors. In 14/553 cervical scrape specimens (2.1%), no agree-
ment was found; of these, 5 were INNO LiPA negative/AM-
PLICOR positive and 9 samples were SPF10-LiPA positive/
AMPLICOR negative. HPV33 was missed twice, and HPV51
and HPV52 were missed in three cases by the AMPLICOR
test. Although these HPV types were identified by both HPV
tests in the majority of the positive cases (see Table 2), these
three HPV genotypes need to be watched carefully as addi-
tional studies are performed in the field.
The sensitivity of HPV detection methods is based on the
threshold value of the viral load/viral concentration. Amplifi-
cation detection assays, such as PCR-based techniques, are
highly sensitive (low threshold of viral load detection), in com-
parison with liquid hybridization tests (high threshold), for
example, the Digene Hybrid Capture 2 test. Snijders et al. have
defined “analytical” and “clinical” sensitivity and specificity in
order to distinguish clinically irrelevant and clinically relevant
HPV positivity rates (39). Analytical sensitivity is defined as
the proportion of HPV-positive women who are correctly iden-
tified by a given test (but clinically unimportant), whereas
clinical sensitivity identifies the proportion of women with dis-
ease (i.e., women with CIN 3) who are correctly identified by
a positive HPV test. However, it must be remembered that
HPV infection indicates a risk of having or developing a cer-
vical lesion and is not equivalent to a morphological disorder.
Though the natural history of HPV infections is not fully un-
derstood, the viral load is probably low during the first phase of
infection but may increase over time, in parallel with the de-
velopment of cytological disorders (38). Therefore, sensitive
methods to diagnose HPV infection may be required in order
to realize a maximum negative predictive value for the devel-
opment of HPV-associated cervical carcinoma, particularly
since most cervical smears are classified as normal or ASCUS.
New insights in the viral load threshold, however, may direct
the future management of HR HPV-positive women, since a
high viral load seems to be indicative for viral persistence and
disease development while a low viral load is associated with
clearance of an infection and even regression of cervical le-
sions, as had been reviewed recently (39).
Most current HPV screening protocols identify the presence
of one of a pool of HR HPV types but do not identify the
individual genotype or determine whether repeated positive
tests are due to the persistence of one particular type; women
who are infected with any HR HPV type are treated in the
same way. On the other hand, Wallin and coworkers have
found a strong concordance between the type of HPV found in
the baseline smear, before the development of cervical carci-
noma, and the HPV type found in the biopsy specimen of the
invasive cancer (44), indicating that neoplasia is associated
with HPV type-specific persistence. Therefore, future manage-
ment of patients with neoplasia will probably include not only
HPV detection but HPV genotyping as well.
It should also be considered that both the Hybrid Capture II
assay and the AMPLICOR HPV Test do not detect HPV26,
	53, 	66, 	73, and 	82, HPV types that have been classified
as probably HR (26, 53, 66) or HR (73, 82) types in a large
epidemiological study of the oncogenic potential of HPV ge-
TABLE 3. Overview of discordant cases
SPF10 LiPA test result
AMPLICOR HPV
test result
HPV X .................................................................................. Positive
HPV11, 	18, 	39, 	68...................................................... Negative
HPV33................................................................................... Negativea
HPV6..................................................................................... Positive
HPV31, 	70 ......................................................................... Negative
Negative ................................................................................ Positive
HPV33................................................................................... Negativeb
HPV X .................................................................................. Positive
HPV11, 	42, 	51, 	52, 	53 ............................................ Negative
HPV52, 	74 ......................................................................... Negative
HPV51................................................................................... Negative
HPV52................................................................................... Negative
HPV51................................................................................... Negative
HPV X .................................................................................. Positive
a Cytological diagnosis: ASCUS.
b Cytological diagnosis: mild/moderate dysplasia.
TABLE 2. Concordant HPV detection and typing in relation to the cytological classification for both PCR tests
Cytology result No. ofsamples
% HR HPV
positive
No. of samples with following HR HPV genotype:
16 18 31 33 35 39 45 51 52 56 58 59 68 Double Triple Multiple
Normal 469 19 18 4 4 2 1 4 2 4 7 3 2 3 1 26 5 2
ASCUS 30 63 5 2 1 1 1 1 3 3 1 1
Mild/moderate dysplasia 27 67 6 1 2 1 1 2 3 2
Severe dysplasia 6 83 1 1 1 1 1
No diagnosis 7 29 1 1
Total 539 24
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notypes (27). In our comparison, we would have missed 11 of
564 (1.9%) infections in women who were found positive for
either HPV53 or HPV66 by the SPF10-LiPA test. Obviously, as
indicated above, these women would not all have developed
cervical lesions or cancer, but Munoz et al. found 1.1% of the
cervical cancers positive for either one of these five types (27).
It is clear that the application of HPV testing in cervical
screening programs will require further improvements in, and
standardization of, testing methods (35). At present, consensus
guidelines on primary screening and/or the triage of women
with mild cytological disorders are lacking because of conflict-
ing data in the existing literature about the prevalence of HPV
in women with normal, mild, or equivocal cytological abnor-
malities. The estimated point prevalence of genital HPV in-
fections among populations of women with normal cytological
smears ranges from 1.5% to 55% (41, 46) and shows an age-
related pattern (25). These differences in the prevalence of
HPV are dependent not only on the screened population but
also on the clinical sample size, menstrual cycle, viral load, and
detection method used for HPV assessment. Incorporation of
HPV detection and typing into primary screening and/or triage
of cytological disorders warrants consensus guidelines and the
use of highly concordant HPV detection methods. Whether
the AMPLICOR HPV Test fulfills these demands should be
further evaluated in further (prospective) clinical studies.
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